Monograph: OLANZapine, OLANZapine Pamoate

OLANZapine, OLANZapine Pamoate

Die Inhalte stehen nur registrierten Benutzern zur Verfügung.

Sie sind zum ersten mal hier und möchten die Datenbank 10-Tage kostenlos testen, dann registrieren Sie sich einmalig. Nach der Registrierung melden Sie sich mit Ihrem Benutzernamen und Passwort an.

Sie sind bereits bei DrugBase registriert und möchten diese Datenbank 10-Tage kostenlos und unverbindlich testen? Dann melden Sie sich mit Ihren Zugangsdaten an und wählen Sie anschließend die Datenbank, die Sie testen möchten.

Full Title

OLANZapine, OLANZapine Pamoate

Generic Name

OLANZapine; OLANZapine Pamoate

Chemical Name

...

INV Number

...

Synonym

...

Classification

CAS Number

...

Introduction

Introduction

...

...

...

Uses

Uses

...

Psychotic Disorders

...

Schizophrenia

...

Pediatric Considerations

...

Acute Agitation

...

Bipolar Disorder

...

Acute Treatment of Manic or Mixed Episodes

...

Combined Therapy

...

Maintenance Monotherapy of Bipolar Disorder

...

Rapid-Cycling Bipolar Disorder

...

Depressive Episodes Associated with Bipolar Disorder

...

Pediatric Considerations

...

Acute Agitation

...

Treatment-resistant Depression

...

Cancer Chemotherapy-induced Nausea and Vomiting

...

Clinical Experience

...

...

Dosage and Administration

Dosage and Administration

...

Reconstitution and Administration

...

Restricted Distribution

...

Oral Administration

...

Dispensing and Administration Precautions

...

IM Administration

...

Short-acting Olanzapine Injection for Acute Agitation associated with Bipolar Disorder or Schizophrenia

...

Extended-release Olanzapine Pamoate Injection for Schizophrenia

...

Dosage

...

Oral Dosage

...

Schizophrenia

...

Bipolar Disorder

...

Table 1. Approximate Dosage Correspondence between Olanzapine in Fixed Combination with Fluoxetine (e.g., Symbyax®) and Combined Olanzapine (e.g., Zyprexa®) and Fluoxetine Therapy (Given Individually).1

...

Treatment-resistant Depression

...

Cancer Chemotherapy-induced Nausea and Vomiting

...

IM Dosage

...

Immediate-release Olanzapine Injection for Acute Agitation associated with Bipolar Disorder or Schizophrenia

...

Extended-release Olanzapine Pamoate Injectable Suspension for Schizophrenia

...

Dosage in Renal and Hepatic Impairment

...

...

Cautions

Cautions

...

Adverse Effects

...

Nervous System Effects

...

Seizures

...

Extrapyramidal Reactions

...

Neuroleptic Malignant Syndrome

...

Tardive Dyskinesia

...

Post-injection Delirium/Sedation Syndrome

...

Other Nervous System Effects

...

Cardiovascular Effects

...

Hemodynamic Effects

...

ECG Effects

...

Other Cardiovascular Effects

...

Hepatic Effects

...

Endocrine and Metabolic Effects

...

Weight Gain

...

Hyperglycemia and Diabetes Mellitus

...

Dyslipidemia

...

Hyperprolactinemia

...

Other Endocrine and Metabolic Effects

...

GI Effects

...

Respiratory Effects

...

Dermatologic and Sensitivity Reactions

...

Drug Reaction with Eosinophilia and Systemic Symptoms

...

Local Effects

...

Genitourinary Effects

...

Musculoskeletal Effects

...

Ocular Effects

...

Hematologic Effects

...

Other Adverse Effects

...

Precautions and Contraindications

...

Laboratory Test Monitoring

...

Hyperprolactinemia

...

Cognitive and Motor Impairment

...

Seizures

...

Body Temperature Regulation

...

Hepatic Effects

...

Drug Reaction with Eosinophilia and Systemic Symptoms

...

Individuals with Phenylketonuria

...

Dysphagia

...

Patients with Concomitant Illness

...

Concomitant Medication or Alcohol Use

...

Tardive Dyskinesia

...

Falls

...

Dispensing and Administration Precautions

...

Leukopenia, Neutropenia, and Agranulocytosis

...

Orthostatic Hypotension

...

Weight Gain

...

Dyslipidemia

...

Hyperglycemia and Diabetes Mellitus

...

Neuroleptic Malignant Syndrome

...

Suicide

...

Geriatric Patients with Dementia-related Psychosis

...

Post-injection Delirium/Sedation Syndrome

...

Contraindications

...

Pediatric Precautions

...

Geriatric Precautions

...

Mutagenicity and Carcinogenicity

...

Pregnancy, Fertility, and Lactation

...

Pregnancy

...

Fertility

...

Lactation

...

...

Drug Interactions

Drug Interactions

...

Drugs Affecting Hepatic Microsomal Enzymes

...

Carbamazepine

...

Selective Serotonin-reuptake Inhibitors

...

Warfarin

...

Drugs Metabolized by Hepatic Microsomal Enzymes

...

Anticholinergic Agents

...

Levodopa and Dopamine Agonists

...

Lamotrigine

...

Other CNS-Active Agents and Alcohol

...

Benzodiazepines

...

Tricyclic Antidepressants

...

Lithium

...

Valproic Acid

...

Alcohol

...

Hypotensive Agents

...

Antacids or Cimetidine

...

Activated Charcoal

...

Smoking

...

Other Drugs

...

...

Chronical Toxicity

Chronic Toxicity

...

...

Acute Toxicity

Acute Toxicity

...

Pathogenesis and Manifestation

...

Treatment

...

...

Pharmacology

Pharmacology

...

Nervous System Effects

...

Antidopaminergic Effects

...

Serotonergic Effects

...

Anticholinergic Effects

...

Effects on Other Central Neurotransmitters

...

Neurophysiologic Effects

...

Cognitive Effects in Humans

...

EEG Effects

...

Effects on Sleep

...

Neuroendocrine Effects

...

Antiemetic Effects

...

...

Pharmacokinetics

Pharmacokinetics

...

Absorption

...

Distribution

...

Elimination

...

...

Chemistry and Stability

Chemistry and Stability

...

Chemistry

...

Stability

...

...

Preparations

Preparations

...

OLANZapine

...

OLANZapine Combinations

...

OLANZapine Pamoate

...

...

REMS

...

References

References

...

...

Copyright

AHFS® Drug Information. © Copyright, 1959-2020, Selected Revisions November 12, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

Quelle

AHFS Drug Information